What GLP-1 users should know about the potential risk of a rare type of vision loss

Key Points:

• Dozens of Americans have filed personal injury lawsuits against makers of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, alleging inadequate warnings about the rare risk of nonarteritic anterior ischemic optic neuropathy (NAION), a sudden vision loss condition.
• Researchers have noted a possible link between GLP-1 drugs and NAION since a 2024 safety signal from a Boston health center, but no conclusive evidence has proven these medications cause the condition.
• Novo Nordisk and Lilly, manufacturers of these drugs, deny the claims, emphasizing ongoing safety monitoring and collaboration with regulators, while the FDA continues to evaluate the potential risk without currently requiring NAION warnings on labels.
• NAION is a rare but serious condition causing permanent vision loss due to reduced optic nerve blood flow, primarily affecting people over 50 and those with diabetes, who are already at increased risk regardless of GLP-1 use.
• Experts advise patients to consult their doctors before stopping GLP-1 medications, noting the significant benefits of these drugs for diabetes and obesity management, while recommending prompt eye exams if sudden vision loss occurs.